FDA Introduces Spectral Library - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Introduces Spectral Library
FDA, in cooperation with IPEC, is building a spectral library of excipients to detect improper ingredients within a drug product on site.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 67-70

Questions and answers

The following section addresses anticipated questions about the spectral library project and the collection of samples. Answers are provided by the authors, representing DPA and IPEC.

What instruments will be used for screening excipients?

DPA plans to build two libraries, one for NIR and one for Raman spectroscopy. These are both common techniques used in library searches because their spectral features are highly sensitive to chemical structure. Both have become increasingly common in portable instrumentation due to their ability to sample through various common sampling media. Some excipients may not be suitable for both libraries because of some inherent limitations of each technique that must be taken into account when populating spectral libraries. An NIR spectrum is dependent on moisture content and particle size, for example. It contains broad and generally weak spectral features (due to sampling of overtone and combination bands). Raman features tend to be sharper and do not depend on moisture or particle size, but if a sample fluoresces, Raman spectral features can be obscured and limit the effectiveness of the library method. Some of the limitations for these two techniques can be reduced using common preprocessing techniques, such as multiplicative scatter correction or first derivative preprocessing. The results of library searches are strongly dependent on (and often enhanced by) spectral preprocessing.

How will a sample spectrum be matched to the libraries?

The typical library search consists of correlating the full spectrum of a test (unknown) sample to a reference (library) spectrum using the Hit Quality Index (HQI), shown in the following equation:



where the indicates the scalar product of the two vectors. As such, library searches are aimed at gauging the full spectrum correlation of two spectra as opposed to focusing on a particular region or peak. The HQI values in the above equation range from 0 to 1.000, with 1.000 indicating a perfect match. This match is achieved when the unknown spectrum is identical to the library spectrum. FDA plans to use this concept when it implements its libraries.

How many materials are expected to be in the library?


Table I: List of priority excipients to be collected for spectral library.
DPA has identified 166 excipients that fit in one or more of the following categories: most commonly used, most vulnerable to adulteration, or needing an update of the US Pharmacopeia monograph. From this list, FDA has narrowed down a priority list of excipients (see Table I). Once library entries for these priority materials have been obtained, the library will be deployed to field inspectors along with any other excipients that have been received. The library will continue to be expanded as additional excipients are received.

What additional types of data are being considered for this library?

Both an NIR and Raman library will be built. These libraries will contain the spectrum of each excipient. In addition to the spectrum, each entry will contain the chemical name, date added, and spectrometer details. When the library search algorithm can distinguish between different manufacturers and/or sites of manufacture of the same excipient, such further identifying information will be included.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here